ESMO

• 

ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

By Sharon Kell|2020-09-18T08:52:36+00:0018 Sep 2020|Uncategorized|

Over the past 2 years, the use of combination therapies [...]

Read More

Comments Off on ESMO Virtual 2020: Four-year follow-up data from nivolimuab plus ipilimumab in metastatic kidney cancer

• 

Managing cancer patients during the COVID-19 pandemic

By Sharon Kell|2020-08-11T08:43:31+00:0011 Aug 2020|Uncategorized|

The European Society for Medical Oncology (ESMO) has released a [...]

Read More

Comments Off on Managing cancer patients during the COVID-19 pandemic

• 

Artificial intelligence and immuno-oncology

By Sharon Kell|2019-12-19T17:45:46+00:0019 Dec 2019|Cancer news|

The use of artificial intelligence (AI) in clinical practice using [...]

Read More

Comments Off on Artificial intelligence and immuno-oncology

• 

ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

By Sharon Kell|2019-09-30T08:45:55+00:0030 Sep 2019|Drug treatments|

Results from the SORCE clinical trial to assess sorfenib as [...]

Read More

Comments Off on ESMO 2019: Results from SORCE clinical trial with adjuvant sorafenib

• 

ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer

By Sharon Kell|2019-09-30T08:35:52+00:0030 Sep 2019|Drug treatments|

Results from the ENTRATA clinical trial to assess telaglenastat in [...]

Read More

Comments Off on ESMO 2019: Results from ENTRATA clinical trial with telaglenastat plus everolimus for pre-treated kidney cancer